8-K 1 d8k.htm FORM 8-K Form 8-K





Washington, D.C. 20549







Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

March 2, 2011

Date of Report (Date of Earliest Event Reported)




(Exact Name of Registrant as Specified in its Charter)


Delaware   1-10269   95-1622442
(State of Incorporation)   (Commission File Number)  

(IRS Employer

Identification Number)

2525 Dupont Drive

Irvine, California 92612

(Address of Principal Executive Offices) (Zip Code)

(714) 246-4500

(Registrant’s Telephone Number, Including Area Code)


(Former Name or Former Address, if Changed Since Last Report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




Item 5.02.    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 2, 2011, F. Michael Ball provided notice to Allergan, Inc. (the “Company”) that he would retire from the Company and resign from his position as President, effective March 27, 2011.

On March 7, 2011, the Company announced that its Board of Directors has reappointed David E.I. Pyott as President. Mr. Pyott will also continue to serve the Company in his current roles as Chairman of the Board and Chief Executive Officer. Mr. Pyott’s role as President succeeds the duties performed by Mr. Ball and will be effective March 27, 2011.

Item 9.01.    Financial Statements and Exhibits.


(d) Exhibits.


99.1   Allergan, Inc. press release dated March 7, 2011


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date:   March 7, 2011     By:   /s/ Matthew J. Maletta
      Name:   Matthew J. Maletta
      Title:   Vice President,
        Associate General Counsel and Secretary

Exhibit Index




Description of Exhibit

99.1    Allergan, Inc. press release dated March 7, 2011